03-18-2022 | Cardiovascular outcomes | News
The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.
03-02-2022 | Empagliflozin | Video
Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.
02-28-2022 | Canagliflozin | News
The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.
04-28-2022 | Nephropathy | News
04-25-2022 | Dapagliflozin | News
04-14-2022 | Prediabetes | News
04-12-2022 | SGLT2 inhibitors | News
03-30-2022 | Healthcare systems | News
03-29-2022 | Cardiovascular disorders | News
03-16-2022 | Heart failure | News
03-09-2022 | Dyslipidemia | News
Get the latest developments in diabetes delivered straight to your inbox